Updated on 2024/03/06

写真a

 
Sakai Kosei
 
Organization
Graduate School of Veterinary Science Department of Veterinary Science Lecturer
School of Veterinary Science Department of Veterinary Science
Title
Lecturer
Affiliation
Institute of Veterinary Science
Contact information
メールアドレス
Affiliation campus
Rinku Campus

Position

  • Graduate School of Veterinary Science Department of Veterinary Science 

    Lecturer  2022.04 - Now

  • School of Veterinary Science Department of Veterinary Science 

    Lecturer  2022.04 - Now

Degree

  • 博士(獣医学) ( The University of Tokyo )

Research Areas

  • Life Science / Veterinary medical science

Research subject summary

  • 犬猫の腫瘍に対する病態解析と新しい診断法・治療法の開発

  • 犬猫の慢性消化器疾患に対する病態解析と新しい診断法・治療法の開発

Research Career

  • 犬猫の腫瘍に対する病態解析と新しい診断法・治療法の開発

    Individual

    2012.09 - Now 

  • 犬猫の慢性消化器疾患に対する病態解析と新しい診断法・治療法の開発

    Individual

    2015.06 - Now 

Professional Memberships

  • 日本獣医学会

    2018.08 - Now   Domestic

  • 日本獣医臨床病理学会

    2019.04 - Now   Domestic

  • 日本獣医がん学会

    2013.05 - 2021.04   Domestic

  • 日本獣医腎泌尿器学会

    2018.04 - Now   Domestic

  • 日本ペット栄養学会

    2019.04 - Now   Domestic

  • 日本獣医師会

    2021.07 - Now   Domestic

  • 獣医がん分子生物学研究会

    2018.09 - Now   Domestic

▼display all

Committee Memberships (off-campus)

  • 臨床研究委員会   日本獣医がん学会  

    2023.04 - Now 

  • 運営委員会   令和5年度獣医学術近畿地区学会  

    2022.01 - Now 

Awards

  • 令和3年度日本獣医師会獣医学術学会年次大会 獣医学術学会賞

    酒居幸生, 茂木朋貴, チェンバーズ ジェームズ, 内田和幸, 西田英高, 島村俊介, 谷 浩行, 嶋田照雅, 古家 優

    2022.02   「DMD遺伝子におけるフレームシフト変異が同定されたトイ・プードルの筋ジストロフィーの1例」

  • 地区学会長

    2021.10   令和3年度獣医学術近畿地区学会  

     More details

    Country:Japan

  • 最優秀賞

    2021.10   日本ペット栄養学会第22回定例大会  

     More details

    Country:Japan

  • 令和3年度獣医学術近畿地区学会 地区学会長賞

    酒居幸生, 茂木朋貴, チェンバーズ ジェームズ, 内田和幸, 西田英高, 島村俊介, 谷 浩行, 嶋田照雅, 古家 優

    2021.10   「DMD遺伝子におけるフレームシフト変異が同定されたトイ・プードルの筋ジストロフィーの1例」

  • 研究発表部門 優秀賞

    2019.08   日本獣医腎泌尿器学会  

     More details

    Country:Japan

  • インターズー学術奨励賞

    2019.02   日本獣医内科学アカデミー  

  • Young Investigator Award

    2015.09   8th International Conference on Annexins,  

  • 北里賞

    2015.03   北里大学  

     More details

    Country:Japan

  • 北島賞

    2013.04   北里大学  

     More details

    Country:Japan

  • 北島賞

    2012.04   北里大学  

     More details

    Country:Japan

▼display all

Job Career (off-campus)

  • 日本学術振興会 特別研究員 (DC2)

    2017.04 - 2019.03

Papers

  • Evaluating the indicators of a heart rate variability analysis in dogs using Poincaré plots Reviewed

    Taichi Kimura, Shunsuke Shimamura, Hiroshi Sakaya, Tetsuya Hayashi, Azusa Umemoto, Kosei Sakai, Masahiro Yamasaki, Tetsuya Hasegawa, Terumasa Shimada

    Veterinarni Medicina   69 ( 2 )   42 - 51   2024.02

     More details

    Publishing type:Research paper (scientific journal)   International / domestic magazine:International journal  

    DOI: 10.17221/49/2023-VETMED

  • A pilot study for the development of a novel diagnostic index based on plasma amino acid concentrations to differentiate chronic enteropathy and alimentary lymphoma in dogs Reviewed

    Kosei Sakai, Masaru Furuya, Shingo Hatoya, Ryoji Kanegi, Tomoyo Nabetani, Shunsuke Shimamura

    Journal of Pet Animal Nutrition   26 ( 1 )   8 - 18   2023.04

     More details

    Authorship:Lead author, Corresponding author   Publishing type:Research paper (scientific journal)   International / domestic magazine:Domestic journal  

  • イヌの慢性腸症と消化器型リンパ腫を鑑別する血漿中アミノ酸濃度を用いた新規診断指標の開発に向けたパイロットスタディ(A pilot study for the development of a novel diagnostic index based on plasma amino acid concentrations to differentiate chronic enteropathy and alimentary lymphoma in dogs)

    酒居 幸生, 古家 優, 鳩谷 晋吾, 金城 綾二, 鍋谷 知代, 島村 俊介

    ペット栄養学会誌   26 ( 1 )   8 - 18   2023.04( ISSN:1344-3763

     More details

    イヌの慢性腸症(CE)と消化器型リンパ腫(AL)は早期の鑑別が重要である。しかし、その鑑別では一般的に全身麻酔下での組織生検を必要とする。血漿中アミノ酸濃度は通常一定に保たれているが、疾患の存在により特徴的な変化を示す。また、採血は組織生検に比べて侵襲性が極めて低い。そこで本研究では、イヌのCEとALの鑑別における血中アミノ酸濃度の有用性を検討した。CEまたはALに罹患するイヌから血漿を採取し、36種類のアミノ酸濃度を液体クロマトグラフィー質量分析法により測定した。2群における各アミノ酸濃度の相関比を算出し、相関比の大きい順にアミノ酸を選択して判別分析を行った。CE群とAL群にはそれぞれ6頭のイヌが組み入れられた。2群間で年齢や性別、不妊手術の実施状況、症状の重症度、ステロイド投与歴に有意差は認められなかった。測定したアミノ酸のうち、26種類が全頭で評価可能であった。これらの中からシトルリン、グルタミンおよびオルニチンを組み合わせて2群の判別式を作成したところ、その相関比は0.8228、判別的中率は100%、誤判別の確率は2.5%であった。以上のことから、血漿中アミノ酸濃度によりイヌのCEとALを簡易かつ正確に判別できる可能性が示された。(著者抄録)

  • Mesenteric lymph node abscesses due to <i>Escherichia coli</i> in a cat Reviewed

    Kosei Sakai, Ryoji Kanegi, Tomoyo Nabetani, Toshiyuki Tanaka, Shunsuke Shimamura, Terumasa Shimada, Kikuya Sugiura, Shingo Hatoya

    Veterinary Medicine and Science   8 ( 4 )   1611 - 1616   2022.07( ISSN:2053-1095

     More details

    Authorship:Lead author, Corresponding author   Publishing type:Research paper (scientific journal)  

    DOI: 10.1002/vms3.840

    Other URL: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/vms3.840

  • Dystrophin-deficient muscular dystrophy in a Toy Poodle with a single base pair insertion in exon 45 of the <i>Duchenne muscular dystrophy</i> gene Reviewed

    Kosei Sakai, Tomoki Motegi, James Ken Chambers, Kazuyuki Uchida, Hidetaka Nishida, Shunsuke Shimamura, Hiroyuki Tani, Terumasa Shimada, Masaru Furuya

    The Journal of Veterinary Medical Science   84 ( 4 )   502 - 506   2022.04

     More details

    Authorship:Lead author, Corresponding author   Publishing type:Research paper (scientific journal)   International / domestic magazine:International journal  

    A 10-month-old, intact male Toy Poodle was referred for a postural abnormality. Blood biochemical tests revealed a marked increase in plasma creatine phosphokinase (CPK) concentration. The isoenzyme test showed that 99% of serum CPK consisted of CPK-MM. Histopathological evaluation of muscle biopsy samples confirmed scattered degeneration and necrosis of myofibers. Immunohistochemistry for dystrophin showed an absence of staining in muscle cells. Based on these findings, the dog was diagnosed with dystrophin-deficient muscular dystrophy. Whole genome sequencing using genomic DNA extracted from blood revealed a single base pair insertion in exon 45 of the Duchenne muscular dystrophy (DMD) gene. This is the first report on muscular dystrophy in Toy Poodles and identified a novel mutation in the DMD gene.

    DOI: 10.1292/jvms.21-0504

    PubMed

  • Retrospective evaluation of nimustine use in the treatment of feline lymphoma Reviewed

    Kosei Sakai, Shingo Hatoya, Masaru Furuya, Tomoyo Nabetani, Ryoji Kanegi, Shunsuke Shimamura, Hiroyuki Tani, Terumasa Shimada

    Veterinary Medicine and Science   8 ( 1 )   3 - 8   2022.01( ISSN:2053-1095

     More details

    Authorship:Lead author, Corresponding author   Publishing type:Research paper (scientific journal)   International / domestic magazine:International journal  

    BACKGROUND: Nimustine, similar to lomustine, is an alkylating agent from the nitrosourea family. There have been some reports regarding lomustine treatment for tumour-bearing cats. However, information regarding nimustine treatment for tumour-bearing cats is limited. OBJECTIVES: To retrospectively evaluate adverse events and clinical outcomes in tumour-bearing cats receiving nimustine. METHODS: Information regarding diagnosis, treatment condition, adverse events, and clinical outcomes was collected in tumour-bearing cats receiving nimustine through reviews of medical records. RESULTS: Nine cats with lymphoma were treated with nimustine in the primary therapy (n = 2) and in the rescue therapy (n = 7). Median starting dose of nimustine was 25 mg/m2 (range: 20-30 mg/m2 ) with dosing interval of three weeks and 1-11 administrations. Adverse events were mild gastrointestinal toxicity (grade 1) including diarrhoea (n = 2) and vomiting (n = 2) and mild myelosuppression (grade 1 or 2) including thrombocytopenia (n = 3) and neutropenia (n = 1). No severe adverse events were observed. Progression-free survival durations among cats receiving nimustine in the primary therapy and in the rescue therapy were 274-688 days (median: 481 days) and 9-671 days (median: 102 days), respectively. Overall survival durations among cats receiving nimustine in the primary therapy and in the rescue therapy were 275-745 days (median: 510 days) and 14-671 days (median: 109 days), respectively. CONCLUSIONS: Nimustine was well tolerated and showed clinical outcomes similar to lomustine in cats with lymphoma. These findings suggest that nimustine might be an alternative to lomustine in the treatment of feline lymphoma.

    DOI: 10.1002/vms3.652

    PubMed

    Other URL: https://onlinelibrary.wiley.com/doi/full-xml/10.1002/vms3.652

  • Lapatinib as first-line treatment for muscle-invasive urothelial carcinoma in dogs Reviewed

    Shingo Maeda, Kosei Sakai, Kenjiro Kaji, Aki Iio, Maho Nakazawa, Tomoki Motegi, Tomohiro Yonezawa, Yasuyuki Momoi

    Scientific Reports   12 ( 1 )   4   2022.01

     More details

    Publishing type:Research paper (scientific journal)   International / domestic magazine:International journal  

    <title>Abstract</title>Epidermal growth factor receptors 1 and 2 (EGFR and HER2) are frequently overexpressed in various malignancies. Lapatinib is a dual tyrosine kinase inhibitor that inhibits both EGFR and HER2. Although a phase III trial failed to show the survival benefits of lapatinib treatment after first-line chemotherapy in patients with EGFR/HER2-positive metastatic urothelial carcinoma, the efficacy of lapatinib for untreated urothelial carcinoma is not well defined. Here, we describe the therapeutic efficacy of lapatinib as a first-line treatment in a canine model of muscle-invasive urothelial carcinoma. In this non-randomized clinical trial, we compared 44 dogs with naturally occurring urothelial carcinoma who received lapatinib and piroxicam, with 42 age-, sex-, and tumor stage-matched dogs that received piroxicam alone. Compared to the dogs treated with piroxicam alone, those administered the lapatinib/piroxicam treatment had a greater reduction in the size of the primary tumor and improved survival. Exploratory analyses showed that HER2 overexpression was associated with response and survival in dogs treated with lapatinib. Our study suggests that lapatinib showed encouraging durable response rates, survival, and tolerability, supporting its therapeutic use for untreated advanced urothelial carcinoma in dogs. The use of lapatinib as a first-line treatment may be investigated further in human patients with urothelial carcinoma.

    DOI: 10.1038/s41598-021-04229-0

    Other URL: https://www.nature.com/articles/s41598-021-04229-0

  • Influence of hypomagnesemia on disease severity and prognosis in dogs with lymphocytic-plasmacytic enteritis Reviewed

    Kosei Sakai, Shingo Hatoya, Masaru Furuya, Shunsuke Shimamura, Tomoyo Nabetani, Hiroyuki Tani, Terumasa Shimada

    Journal of Pet Animal Nutrition 雑誌   2021.04

     More details

    Kind of work:Joint Work  

  • Human epidermal growth factor receptor 2 is overexpressed in canine prostate carcinoma Reviewed

    Kosei Sakai, Yuri Shinohara, Kenjiro Kaji, Tomohiro Yonezawa, Yasuyuki Momoi, Shingo Maeda

    Translational and Regulatory Sciences   3 ( 1 )   2021.04

  • Influence of hypomagnesemia on disease severity and prognosis in dogs with lymphocytic-plasmacytic enteritis Reviewed

    Kosei SAKAI, Shingo HATOYA, Masaru FURUYA, Shunsuke SHIMAMURA, Tomoyo NABETANI, Hiroyuki TANI, Terumasa SHIMADA

    Journal of Pet Animal Nutrition   24 ( 1 )   1 - 13   2021.04( ISSN:1344-3763

     More details

    Authorship:Lead author, Corresponding author   Publishing type:Research paper (scientific journal)  

    DOI: 10.11266/jpan.24.1_1

    J-GLOBAL

  • イヌ乳癌においてErbB2コピー数獲得は有害転帰と関連する(ErbB2 copy number gain is associated with adverse outcome in canine mammary carcinoma)

    Sakai Kosei, Chambers James Ken, Uchida Kazuyuki, Nakagawa Takayuki, Nishimura Ryohei, Yonezawa Tomohiro, Maeda Shingo

    The Journal of Veterinary Medical Science   83 ( 3 )   370 - 377   2021.03( ISSN:0916-7250

  • Protease-Activated Receptor-2 Is Associated With Adverse Outcomes in Canine Mammary Carcinoma Reviewed

    Kenjiro Kaji, Noriyuki Kaji, Masatoshi Hori, Kosei Sakai, Tomohiro Yonezawa, Shingo Maeda

    Veterinary Pathology   58 ( 1 )   53 - 62   2021.01( ISSN:0300-9858

     More details

    Publishing type:Research paper (scientific journal)   International / domestic magazine:International journal  

    Protease-activated receptor-2 (PAR2) is a G protein–coupled receptor that is activated by serine proteases. In humans, PAR2 is highly expressed in various cancers, including breast cancer, and is associated with cancer progression and metastasis. However, the expression and roles of PAR2 in canine mammary carcinoma remain unclear. The purpose of this study was to examine the expression of PAR2 in canine mammary carcinoma, the association between PAR2 expression and clinical characteristics, and the role of PAR2 in the metastatic phenotypes of tumor cells. Mammary carcinoma from 31 dogs and 10 normal mammary glands were included in this study, and used for immunohistochemical analysis of PAR2 expression. Normal mammary glands did not express PAR2. In contrast, mammary carcinomas showed PAR2 immunoreactivity in the cytoplasm, and its expression level varied between specimens from negative to strongly positive. The overall survival of dogs with high PAR2 expression was shorter than that of dogs with low PAR2 expression. Moreover, PAR2 expression level was associated with the presence of lymph node involvement, advanced clinical stage, and high histopathological grade. In vitro analyses revealed that a PAR2 agonist accelerated cell migration and invasion in a canine mammary carcinoma cell line. In addition, the PAR2 agonist induced epithelial-mesenchymal transition and actin polymerization. These results suggest that PAR2 expression plays a role in tumor progression and clinical outcomes in canine mammary carcinoma.

    DOI: 10.1177/0300985820963087

    PubMed

    Other URL: http://journals.sagepub.com/doi/full-xml/10.1177/0300985820963087

  • ErbB2 copy number gain is associated with adverse outcome in canine mammary carcinoma Reviewed

    Kosei SAKAI, James Ken CHAMBERS, Kazuyuki UCHIDA, Takayuki NAKAGAWA, Ryohei NISHIMURA, Tomohiro YONEZAWA, Shingo MAEDA

    The Journal of Veterinary Medical Science   2021

     More details

    Kind of work:Joint Work  

  • Human epidermal growth factor receptor 2 is overexpressed in canine prostate carcinoma Reviewed

    Kosei SAKAI, Yuri SHINOHARA, Kenjiro KAJI, Tomohiro YONEZAWA, Yasuyuki MOMOI, Shingo MAEDA

    Translational and Regulatory Sciences   3 ( 1 )   1 - 8   2021

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)  

    DOI: 10.33611/trs.2020-018

  • <i>ErbB2</i> copy number gain is associated with adverse outcome in canine mammary carcinoma Reviewed

    Kosei SAKAI, James Ken CHAMBERS, Kazuyuki UCHIDA, Takayuki NAKAGAWA, Ryohei NISHIMURA, Tomohiro YONEZAWA, Shingo MAEDA

    Journal of Veterinary Medical Science   83 ( 3 )   370 - 377   2021( ISSN:0916-7250

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)   International / domestic magazine:Domestic journal  

    Copy number gain (CNG) and/or protein overexpression of ErbB2 have been observed in human breast cancer patients and are associated with poor prognosis. Similarly, ErbB2 overexpression has also been observed in canine mammary carcinoma; however, data on ErbB2 copy number is limited. The purposes of this study were to evaluate ErbB2 copy number in dogs with mammary carcinoma and to investigate associations of ErbB2 CNG with ErbB2 expression, histological and clinical characteristics, and survival. DNA samples were isolated from 59 formalin-fixed paraffin-embedded canine mammary gland tissues (34 carcinoma, 14 adenoma, and 11 normal). Using a digital PCR assay, the ErbB2 copy number in these samples was determined as compared to a reference gene on canine chromosome 8. ErbB2 CNG was detected in 14/34 (41%) carcinomas and 2/14 (14%) adenomas. ErbB2 overexpression was observed in 3/34 (9%) carcinomas but not in adenomas. Neither ErbB2 CNG nor ErbB2 overexpression were detected in the normal controls. There was no significant association of the ErbB2 CNG with histological and clinical characteristics such as age, neutered status, histological grade, tumor size, lymph node involvement, distant metastasis, and clinical stage in the dogs with mammary carcinoma. The presence of ErbB2 CNG, but not ErbB2 overexpression, was significantly related to the shorter overall survival. These findings suggest that ErbB2 CNG is a prognostic factor in dogs with mammary carcinoma.

    DOI: 10.1292/jvms.20-0483

    PubMed

  • Protease-Activated Receptor-2 Is Associated With Adverse Outcomes in Canine Mammary Carcinoma Reviewed

    Kaji K, Kaji N, Hori M, Sakai K, Yonezawa T, Maeda S

    Veterinary Pathology   2020.10

     More details

    Kind of work:Joint Work  

  • リンパ球形質細胞性腸炎のイヌにおける血清亜鉛濃度低下、およびその疾患重症度および予後との関連性(Decreased serum zinc concentration in dogs with lymphocytic-plasmacytic enteritis, and its associations with disease severity and prognosis)

    Sakai Kosei, Hatoya Shingo, Furuya Masaru, Shimamura Shunsuke, Nabetani Tomoyo, Tani Hiroyuki, Shimada Terumasa

    The Journal of Veterinary Medical Science   82 ( 6 )   759 - 763   2020.06( ISSN:0916-7250

  • Decreased serum zinc concentration in dogs with lymphocytic-plasmacytic enteritis, and its associations with disease severity and prognosis Reviewed

    Kosei Sakai, Shingo Hatoya, Masaru Furuya, Shunsuke Shimamura, Tomoyo Nabetani, Hiroyuki Tani, Terumasa Shimada

    The Journal of Veterinary Medical Science   2020.04

     More details

    Kind of work:Joint Work  

  • <i>ErbB2</i> Copy Number Aberration in Canine Urothelial Carcinoma Detected by a Digital Polymerase Chain Reaction Assay Reviewed

    Kosei Sakai, Shingo Maeda, Kohei Saeki, Ryohei Yoshitake, Yuko Goto-Koshino, Takayuki Nakagawa, Ryohei Nishimura, Tomohiro Yonezawa, Naoaki Matsuki

    Veterinary Pathology   57 ( 1 )   56 - 65   2020.01( ISSN:0300-9858

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)  

    Urothelial carcinoma (UC) is the most common tumor affecting the urinary bladder of dogs. Protein overexpression of ErbB2 (the canine homolog of HER2) has been observed in dogs with UC. However, no study regarding ErbB2 copy number aberration (CNA) is reported in dogs with UC. In this study, a digital PCR assay for detecting CNA of canine ErbB2 was developed. DNA samples were isolated from 83 formalin-fixed, paraffin-embedded urinary bladder tissues (36 UC, 8 polypoid cystitis, and 39 normal) and 94 urinary sediments (54 UC, 30 nonneoplastic, and 10 normal). The copy number of canine chromosome 8 ( CFA8) was used as a control. In the urinary bladder tissues, ErbB2 CNA was detected in 12 of 36 (33%) UC, 2 of 8 (25%) polypoid cystitis, and 0 of 39 (0%) normal controls. In the urinary sediments, ErbB2 CNA was also detected in 19 of 54 (35%) UC; however, no ErbB2 CNA was detected in nonneoplastic diseases or normal controls. The sensitivity and specificity of ErbB2 CNA in urinary sediment for the detection of UC were 35% and 100%, respectively. There was a positive correlation between the copy number ratios of ErbB2 to CFA8 in the urinary bladder tissues and urinary sediments. Our findings indicate that the digital PCR assay of urinary sediments may be a useful, noninvasive method for detecting ErbB2 CNA in dogs with UC.

    DOI: 10.1177/0300985819879445

    PubMed

    Other URL: http://journals.sagepub.com/doi/full-xml/10.1177/0300985819879445

  • Decreased serum zinc concentration in dogs with lymphocytic-plasmacytic enteritis, and its associations with disease severity and prognosis Reviewed

    Kosei SAKAI, Shingo HATOYA, Masaru FURUYA, Shunsuke SHIMAMURA, Tomoyo NABETANI, Hiroyuki TANI, Terumasa SHIMADA

    The Journal of Veterinary Medical Science   82 ( 6 )   759 - 763   2020( ISSN:0916-7250

     More details

    Authorship:Lead author, Corresponding author   Publishing type:Research paper (scientific journal)   International / domestic magazine:Domestic journal  

    Human patients with inflammatory bowel disease may have poor prognosis with hypozincemia. However, there are limited data on zinc concentrations in the blood of dogs with lymphocytic-plasmacytic enteritis (LPE). The purpose of this study was to investigate the serum zinc concentration in dogs with LPE and its influence on disease severity and prognosis. Thirty-five dogs with LPE were recruited. Serum zinc concentration was measured using atomic absorption spectrometry. Hypozincemia was observed in 18/35 (51%) dogs with LPE. Serum zinc concentration was inversely correlated with histological and clinical severities. Overall survivals were significantly shorter in dogs with hypozincemia than in those without it. These findings suggest that serum zinc concentration is a useful biomarker for LPE severity and prognosis in dogs.

    DOI: 10.1292/jvms.20-0109

    PubMed

  • Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder Reviewed

    Masaya Tsuboi*, Kosei Sakai*, Shingo Maeda, James K. Chambers, Tomohiro Yonezawa, Naoaki Matsuki, Kazuyuki Uchida, Hiroyuki Nakayama, (*: equal contribution)

    Veterinary Pathology   56 ( 3 )   369 - 376   2019.05( ISSN:0300-9858

     More details

    Authorship:Lead author   Publishing type:Research paper (scientific journal)   International / domestic magazine:International journal  

    Canine urothelial carcinoma (UC) has a poor prognosis and high metastatic rate. Human epidermal growth factor receptor 2 (HER2), a receptor tyrosine kinase involved in cell proliferation and differentiation regulation, has been attracting interest as a therapeutic target molecule for human breast cancer. This study investigated expression of the canine homolog of HER2 (ERBB2) in canine UC, and its association with clinical factors. Since it has been controversial whether commercial anti-human HER2 antibody (Dako A0485) correctly recognizes the canine homolog of HER2, an application of the antibody using a canine UC cell line was validated first. By Western blot, a single band at the appropriate size for canine HER2 (185 kDa) was recognized. Immunohistochemistry for HER2 was performed on 23 samples of UC, 8 samples of polypoid cystitis, and 8 samples of normal urinary bladder, and the results were scored as either 0, 1+, 2+, or 3+ with reference to the evaluation method for human UC. Intense membranous HER2 immunoreactivity was frequently observed in neoplastic cells, especially in grade 2 UC. Minor HER2 expression was found in the epithelial cells of polypoid cystitis and normal bladder. The incidence of HER2 positivity (scores of 2+ or 3+) was 14 of 23 (60.9%) in UC, 3 of 8 (37.5%) in polypoid cystitis, and 0 of 8 (0%) in normal bladder. There was no significant correlation between HER2 positivity and clinical factors. While increased HER2 expression was observed in a subset of urothelial carcinomas, further mechanistic studies are needed to determine its role in the pathogenesis and targeted therapy of this cancer.

    DOI: 10.1177/0300985818817024

    PubMed

    Other URL: http://journals.sagepub.com/doi/full-xml/10.1177/0300985818817024

  • Establishment of human epidermal growth factor receptor 2 (HER2)-targeted therapy for canine transitional cell carcinoma Reviewed

    Sakai K

    The Universuty of Tokyo   2019.03

     More details

    Authorship:Lead author   Publishing type:Doctoral thesis  

    DOI: 10.15083/0002002316

  • Assessment of HER2 Expression in Canine Urothelial Carcinoma of the Urinary Bladder Reviewed

    Tsuboi M*, Sakai K:, Maeda S, Chambers JK, Yonezawa T, Matsuki N, Uchida K, Nakayama H (*: Double first)

    Veterinary pathology   2019.01

     More details

    Kind of work:Joint Work  

  • ErbB2 Copy Number Aberration in Canine Urothelial Carcinoma Detected by a Digital Polymerase Chain Reaction Assay Reviewed

    Sakai K, Maeda S , Saeki K, Yoshitake R, Goto-Koshino Y, Nakagawa T, Nishimura R, Yonezawa T, Matsuki N

    Veterinary Pathology   2019

     More details

    Kind of work:Joint Work  

  • Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines Reviewed

    Sakai K, Maeda S, Saeki K, Nakagawa T, Murakami M, Endo Y, Yonezawa T, Kadosawa T, Mori T, Nishimura R, Matsuki N

    Veterinary and comparative oncology   2018.12

     More details

    Kind of work:Single Work  

  • Association of tumour-infiltrating regulatory T cells with adverse outcomes in dogs with malignant tumours Reviewed

    Sakai K, Maeda S, Yamada Y, Chambers JK, Uchida K, Nakayama H, Yonezawa T, Matsuki N

    Veterinary and comparative oncology   2018.09

     More details

    Kind of work:Joint Work  

  • Decreased plasma amino acid concentrations in cats with chronic gastrointestinal diseases and their possible contribution in the inflammatory response Reviewed

    Sakai K, Maeda S, Yonezawa T, Matsuki N

    Veterinary immunology and immunopathology   2018.01

     More details

    Kind of work:Joint Work  

  • Fecal microbiome in dogs with inflammatory bowel disease and intestinal lymphoma Reviewed

    Omori M, Maeda S, Igarashi H, Ohno K, Sakai K, Yonezawa T, Horigome A, Odamaki T, Matsuki N

    The Journal of veterinary medical science   2017.11

     More details

    Kind of work:Joint Work  

  • Endoscopic Cytology for the Diagnosis of Chronic Enteritis and Intestinal Lymphoma in Dogs Reviewed

    Maeda S, Tsuboi M, Sakai K, Ohno K, Fukushima K, Kanemoto H, Hiyoshi-Kanemoto S, Goto-Koshino Y, Chambers JK, Yonezawa T, Uchida K, Matsuki N

    Veterinary pathology   2017.07

     More details

    Kind of work:Joint Work  

  • Alteration of somatostatin receptor 2 expression in canine mammary gland tumor Reviewed

    Sakai K, Yonezawa T, Yamawaki H, Oyamada T

    The Journal of veterinary medical science   77 ( 10 )   2015.10

     More details

    Kind of work:Joint Work  

▼display all

MISC

▼display all

Presentations

  • イヌ高悪性度消化器型リンパ腫の予後改善に向けた薬剤スクリーニングによる新規治療薬候補の探索 Domestic conference

    平尾雅貴, 島村俊介, 岡村泰彦, 水野拓也, 酒居幸生

    第20回日本獣医内科学アカデミー学術大会 (JVM賞)  2024.02 

     More details

    Presentation type:Oral presentation (general)  

  • 犬におけるNT-proBNPの血清中濃度と尿中濃度の関連についての検討

    松本実優, 島村俊介, 小寺千晶, 森田薫, 平田翔吾, 駒井仁史, 酒居幸生, 谷浩行

    第119回日本獣医循環器学会定例大会  2023.12 

     More details

    Presentation type:Oral presentation (general)  

  • 動物園飼育アジアゾウの血清を用いたアルカリフォスファターゼ(ALP)アイソザイム活性測定における2種類の測定法の比較と凍結保存の影響 Domestic conference

    安達希, 竹鼻一也, 石川真悟, 酒居幸生, 島村俊介, 山岸則夫

    令和5年度獣医学術近畿地区学会  2023.09 

     More details

    Presentation type:Oral presentation (general)  

  • イヌの尿路上皮癌に対する抗HER2抗体療法の効果の検討 Domestic conference

    吉中潤華, 加藤大貴, 高橋洋介, 池田凡子, 青木 督, 井口貴瑛, 石川真悟, 山岸則夫, 島村俊介, 中川貴之, 酒居幸生

    第28回日本獣医がん学会  2023.07 

     More details

    Presentation type:Oral presentation (general)  

  • 知って得する慢性腸症 犬の慢性腸症に対する食事療法のCase study

    酒居 幸生

    Vet Dock セミナー  2022.10  日本小動物歯科研究会・日本獣医臨床病理学会・大阪公立大学獣医臨床センター・日本獣医腎泌尿器学会

  • イヌ口腔内悪性黒色腫の浸潤・転移におけるTGF-βの役割

    中村 友紀, 野口 俊助, 中川 貴之, 島村 俊介, 酒居 幸生

    日本獣医学会学術集会講演要旨集  2022.09  (公社)日本獣医学会

  • イヌ口腔内悪性黒色腫の浸潤・転移におけるTGF-βの役割

    中村友紀, 野口俊助, 中川貴之, 島村俊介, 酒居幸生

    第165回日本獣医学会  2022.09 

     More details

    Presentation type:Oral presentation (general)  

  • イヌ口腔内悪性黒色腫におけるTGF-βオートクリンシグナルとその機能解析(Autocrine TGF-β signaling and its functional analysis in canine oral malignant melanoma)

    酒居 幸生, 中村 友紀, 野口 俊助, 中川 貴之

    日本癌学会総会記事  2022.09  (一社)日本癌学会

  • Autocrine TGF-β signaling and its functional analysis in canine oral malignant melanoma

    Kosei Sakai, Yuki Nakamura, Shunsuke Noguchi, Takayuki Nakagawa

    第81回日本癌学会学術総会  2022.09 

     More details

    Presentation type:Poster presentation  

  • イヌの悪性黒色腫におけるTransforming Growth Factor-βのオートクリンシグナル伝達とその機能解析

    中村友紀, 酒居幸生, 中川貴之, 野口俊助, 島村俊介, 鳩谷晋吾, 嶋田照雅, 杉浦喜久弥

    第18回日本獣医内科学アカデミー学術大会  2022.02 

     More details

    Presentation type:Oral presentation (general)  

  • DMD遺伝子におけるフレームシフト変異が同定されたトイ・プードルの筋ジストロフィーの1例 Invited Domestic conference

    酒居幸生, 茂木朋貴, チェンバーズ ジェームズ, 内田和幸, 西田英高, 島村俊介, 谷 浩行, 嶋田照雅, 古家 優

    令和3年度日本獣医師会獣医学術学会年次大会  2022.01 

     More details

    Presentation type:Poster presentation  

  • DMD遺伝子におけるフレームシフト変異が同定されたトイ・プードルの筋ジストロフィーの1例 Invited

    酒居幸生, 茂木朋貴, チェンバーズ ジェームズ, 内田和幸, 西田英高, 島村俊介, 谷 浩行, 嶋田照雅, 古家 優

    令和3年度日本獣医師会獣医学術学会年次大会 (獣医学術学会賞)  2022.01 

     More details

    Presentation type:Oral presentation (invited, special)  

  • 犬の慢性腸症と消化器型リンパ腫を判別する血中アミノ酸濃度を用いたスコアリングシステムの構築 Domestic conference

    酒居幸生, 古家優, 鳩谷晋吾, 島村俊介, 鍋谷知代, 金城綾二, 谷浩行, 嶋田照雅

    日本ペット栄養学会第22回定例大会  2021.10 

     More details

    Presentation type:Poster presentation  

  • DMD遺伝子におけるフレームシフト変異が同定されたトイ・プードルの筋ジストロフィーの1例 Domestic conference

    酒居幸生, 茂木朋貴, チェンバーズ ジェームズ, 内田和幸, 西田英高, 島村俊介, 谷 浩行, 嶋田照雅, 古家 優

    令和3年度獣医学術近畿地区学会  2021.10 

     More details

    Presentation type:Poster presentation  

  • 犬の慢性腸症における血中マグネシウム濃度と病態との関連 Domestic conference

    酒居幸生, 鳩谷晋吾, 古家 優, 島村俊介, 鍋谷知代, 谷浩行, 嶋田照雅

    日本ペット栄養学会第22回定例大会  2021.10 

     More details

    Presentation type:Poster presentation  

  • 犬の慢性腸症における血中マグネシウム濃度と病態との関連

    酒居 幸生, 鳩谷 晋吾, 古家 優, 島村 俊介, 鍋谷 知代, 谷 浩行, 嶋田 照雅

    ペット栄養学会誌  2021.10  (一社)日本ペット栄養学会

  • 犬の慢性腸症と消化器型リンパ腫を判別するアミノインデックスの構築

    酒居 幸生, 古家 優, 鳩谷 晋吾, 島村 俊介, 鍋谷 知代, 金城 綾二, 谷 浩行, 嶋田 照雅

    ペット栄養学会誌  2021.10  (一社)日本ペット栄養学会

  • DMD遺伝子におけるフレームシフト変異が同定されたトイ・プードルの筋ジストロフィーの1例 Domestic conference

    酒居幸生, 茂木朋貴, チェンバーズ ジェームズ, 内田和幸, 西田英高, 島村俊介, 谷 浩行, 嶋田照雅, 古家 優

    令和3年度獣医学術近畿地区学会 (地区学会長賞)  2021.09 

     More details

    Presentation type:Oral presentation (general)  

  • ACNUをレスキュー療法に用いた大細胞性リンパ腫の猫の6例

    酒居幸生, 鳩谷晋吾, 古家優, 鍋谷知代, 金城綾二, 島村俊介, 谷浩行, 嶋田照雅

    日本獣医臨床病理学会2021年次大会  2021.08 

     More details

    Presentation type:Oral presentation (general)  

  • ウェアラブルデバイスを用いた僧帽弁閉鎖不全犬の自律神経活動に関する検討 Domestic conference

    木村太一, 島村俊介, 酒居幸生, 丸田香緒里, 濱本将樹, 梅本あずさ, 林哲也, 嶋田照雅

    第16回日本獣医内科学アカデミー学術大会  2020.02 

     More details

    Presentation type:Oral presentation (general)  

  • イヌの乳腺癌におけるHER2遺伝子コピー数異常と予後との関連 Domestic conference

    酒居幸生, 前田真吾, 米澤智洋

    日本獣医臨床病理学会2019年大会  2019.06 

     More details

    Presentation type:Oral presentation (general)  

▼display all

Industrial Property Rights

  • 乳腺癌に罹患したイヌ科動物の予後予測方法

    前田 真吾, 酒居 幸生

     More details

    property_type:Patent 

    Application no:特願2022-000691 

    Announcement no:特開2023-100186 

    J-GLOBAL

  • プードル種の筋ジストロフィーを検査する方法

    酒居幸生, 古家優, 茂木朋貴

     More details

    property_type:Patent 

    Application no:特願2021-146736 

  • プードル種の筋ジストロフィーを検査する方法

    酒居 幸生, 古家 優, 茂木 朋貴

     More details

    property_type:Patent 

    Application no:特願2021-146736 

    Announcement no:特開2023-039563 

    J-GLOBAL

  • 食肉目動物の癌検出方法

    前田真吾、酒居幸生

     More details

    property_type:Patent 

    Patent/Registration no:特開2019-126295 

Outline of collaborative research (seeds)

  • 犬悪性黒色腫の病態解析と治療開発

     More details

    犬悪性黒色腫における新規治療標的を発見したため、これに基づく病態解析と治療開発を進めている。

  • 犬と猫の消化器疾患に対する病態解析と新しい診断法・治療法の開発

Grant-in-Aid for Scientific Research

  • 犬固形腫瘍に有効なCAR-T細胞のシグナル分子の解明

    2021

  • 犬固形腫瘍に有効なCAR-T細胞のシグナル分子の解明

    2020

  • 制御性T細胞が犬の腫瘍局所に浸潤する機序解明とその制御

    2017

Social Activities

  • いちばん身近な存在 「ペット」の健康と幸せを守るには

    Role(s): Lecturer

    こうべ動物共生センター 獣医師体験プログラム  2023.09

     More details

    Type:Lecture

  • 犬の下痢に対する系統的アプローチと食事療法の考え方

    Role(s): Lecturer

    ロイヤルカナン  ベテリナリーシンポジウム  2023.07

     More details

    Type:Seminar, workshop

  • いちばん身近な存在 「ペット」の健康と幸せを守るには

    Role(s): Lecturer

    こうべ動物共生センター  獣医師体験プログラム  2022.10

     More details

    Audience: Schoolchildren, Junior high school students

    Type:Lecture

  • 今一度整理しよう!貧血に対する系統的診断アプローチ

    Role(s): Lecturer

    西宮市開業獣医師会  学術講習会  2022.02

     More details

    Type:Seminar, workshop

  • 今一度整理しよう!犬の慢性腸症に対する診断と治療

    Role(s): Lecturer

    大阪府立大学  第4回OPU-VMCオンラインセミナー  2022.01

     More details

    Type:Seminar, workshop

  • いちばん身近な存在 「ペット」の健康と幸せを守るには

    Role(s): Lecturer

    こうべ動物共生センター  獣医師体験プログラム  2021.12

     More details

    Audience: Schoolchildren, Junior high school students

    Type:Lecture

▼display all

Other

  • 研究職歴

    2019.04 - Now

      More details

    大阪府立大学